0001127602-23-018423.txt : 20230609
0001127602-23-018423.hdr.sgml : 20230609
20230609161606
ACCESSION NUMBER: 0001127602-23-018423
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230607
FILED AS OF DATE: 20230609
DATE AS OF CHANGE: 20230609
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Strong Stewart W
CENTRAL INDEX KEY: 0001420910
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-14041
FILM NUMBER: 231005489
MAIL ADDRESS:
STREET 1: C/O HAEMONETICS CORPORATION
STREET 2: 125 SUMMER STREET
CITY: BOSTON
STATE: MA
ZIP: 02110
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: HAEMONETICS CORP
CENTRAL INDEX KEY: 0000313143
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 042882273
STATE OF INCORPORATION: MA
FISCAL YEAR END: 0401
BUSINESS ADDRESS:
STREET 1: 125 SUMMER STREET
CITY: BOSTON
STATE: MA
ZIP: 02110
BUSINESS PHONE: 7818487100
MAIL ADDRESS:
STREET 1: 125 SUMMER STREET
CITY: BOSTON
STATE: MA
ZIP: 02110
4
1
form4.xml
PRIMARY DOCUMENT
X0407
4
2023-06-07
0000313143
HAEMONETICS CORP
HAE
0001420910
Strong Stewart W
125 SUMMER STREET
BOSTON
MA
02110
1
President, Global Hospital
0
Common Stock
2023-06-07
4
M
0
4483
56.57
A
21630
D
Common Stock
2023-06-07
4
M
0
2410
57.60
A
24040
D
Common Stock
2023-06-07
4
F
0
5053
88.00
D
18987
D
Common Stock
2023-06-07
4
S
0
2538
88.04
D
16449
D
Non-qualified Stock Option (Right to Buy)
56.57
2023-06-07
4
M
0
4483
0
D
2023-05-18
2028-05-18
Common Stock
4483
4483
D
Non-qualified Stock Option (Right to Buy)
57.60
2023-06-07
4
M
0
2410
0
D
2023-05-16
2029-05-16
Common Stock
2410
7231
D
This number includes unvested restricted stock units ("RSUs") previously reported.
Represents shares withheld for tax obligations and for payment of the exercise price on exercised stock options reported in Table I.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.96 to $88.12, inclusive. The reporting person undertakes to provide to Haemonetics Corporation ("Haemonetics"), any security holder of Haemonetics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this report.
Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.
/s/ Thomas V. Powers, attorney-in-fact for Mr. Strong
2023-06-09